Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19376207 | 0.86 | GRM5 (0.41) | NAMPTCNR1GRM5EGLN1 | |
| SCHEMBL23210852 | 0.83 | NAMPT (0.46) | NAMPTGRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL1750346 | 0.83 | NAMPT (0.39) | NAMPTGRM5SMN1; SMN2EGLN1 | |
| SCHEMBL28878989 | 0.83 | NAMPT (0.43) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL29907164 | 0.81 | GRM1 (0.55) | NAMPTCNR1GRM5 | |
| SCHEMBL1749492 | 0.81 | GRM1 (0.55) | NAMPTCNR1GRM5 | |
| SCHEMBL30899650 | 0.80 | GRM5 (0.52) | NAMPTCNR1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL30365847 | 0.80 | GRM5 (0.52) | NAMPTCNR1GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL12489502 | 0.80 | CHRM1 (0.52) | NAMPTGRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL13490336 | 0.80 | NAMPT (0.43) | NAMPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | NAMPT 292/4885CNR1 142/4885GRM5 2738/4885 |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | NAMPT 645/4885CNR1 1692/4885GRM5 1935/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | NAMPT 645/4885CNR1 1692/4885GRM5 1935/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | NAMPT 222/4885CNR1 170/4885GRM5 2430/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | NAMPT 645/4885CNR1 1692/4885GRM5 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.